ProPhase Labs, Inc. Manufacturing Costs
ProPhase Labs, Inc. (PRPH) reported Manufacturing Costs of $3.33 million for the 3-month period ending 2018-03-31, per its 10-Q/A filed 2018-08-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ManufacturingCosts · last filed 2018-08-20
- ProPhase Labs, Inc. manufacturing costs for the quarter ending 2018-03-31 was $3.33M.
| Period end | Manufacturing Costs 3 month | Manufacturing Costs 3 month as first filed |
|---|---|---|
| 2018-03-31 | $3.33M 10-Q/A · filed 2018-08-20 | -$3.33M 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |